Sugi Predict

Sugi Predict / Compounds / SCHEMBL31297436

SCHEMBL31297436

SCHEMBL31297436

O=C(O)c1cc(F)c(Br)c(I)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPMT P51580 6/20 0.54
▸ TTR P02766 2/20 0.42
▸ LMNA P02545 3/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ CA12 O43570 2/20 0.40
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ CA7 P43166 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ CA14 Q9ULX7 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ CA3 P07451 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ SELL P14151 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SELP P16109 1/20 0.40
▸ FUT4 P22083 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16049973 0.85 TPMT (0.65) TPMTTTRLMNAMAPK1CA12
SCHEMBL4338424 0.85 TTR (0.50) TPMTTTRLMNAMAPK1CA12
SCHEMBL23815308 0.79 TPMT (0.58) TPMTTTRLMNAMAPK1CA12
SCHEMBL31700576 0.78 ERN1 (0.36) TPMTLMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL16049891 0.78 TPMT (0.56) TPMTTTRLMNAMAPK1CA12
SCHEMBL1313079 0.78 TPMT (0.56) TPMTTTRLMNAMAPK1CA12
SCHEMBL26121716 0.78 KDM4E (0.58) TPMTTTRLMNAMAPK1CA12
SCHEMBL31174965 0.76 TTR (0.52) TPMTTTRLMNAMAPK1CA12
SCHEMBL31049112 0.76 TTR (0.52) TPMTTTRLMNAMAPK1CA12
SCHEMBL31700656 0.76 TPMT (0.45) TPMTTTRLMNAMAPK1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049072-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN ASTELLAS PHARMA INC (JP) 2026-02-19 — — US disclosed
US-20260042771-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN ASTELLAS PHARMA INC. (JP) 2026-02-12 — — US disclosed
EP-4570795-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN Astellas Pharma, Inc. (JP) 2025-06-18 — — EP disclosed
EP-4567033-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN Astellas Pharma Inc. (JP) 2025-06-11 — — EP disclosed
CN-119630656-A Heterocyclic compounds for inducing cleavage of mutant KRAS proteins 安斯泰来制药株式会社 2025-03-14 — — CN disclosed
CN-119604495-A Heterocyclic compounds for inducing G12V mutant KRAS protein degradation 安斯泰来制药株式会社 2025-03-11 — — CN disclosed
WO-2024261256-A1 PHARMACEUTICAL COMPOSITION COMPRISING A pan-KRAS DEGRADER ASTELLAS PHARMA INC. (JP) 2024-12-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042771-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN KRAS, NRAS, HRAS TPMT 4361/4885TTR 4088/4885LMNA 1344/4885
US-20260049072-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN KRAS, NRAS, HRAS TPMT 4095/4885TTR 3522/4885LMNA 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.